LPCN Lipocine Inc
Company Analysis
Latest News
🔴 Lipocine is trading 10% down today amid AI-spending concerns and higher oil
Lipocine is trading at $1.44, down 10.00%, amid a broad market selloff. - Reuters reported the Nasdaq slid more than 2% as mega-cap earnings did little to...
🔴 Lipocine is trading 5% down today as Nasdaq and S&P 500 fall
Lipocine is trading 5% down at $1.52 as broader markets weaken. - Provided market context reports significant declines in the Nasdaq and S&P 500 amid concerns...
🟢 Lipocine is trading 6.54% up today amid a 2.09% biotech sector gain
Lipocine is trading at $1.63, up +6.54%, with broader biotech-sector strength potentially contributing to the move. - No new company-specific announcement was...
🔴 Lipocine is trading 9.29% down — catalyst remains unclear
Lipocine is trading 9.29% down at $1.42, with no confirmed company-specific catalyst identified for the decline. - The stock closed at $1.56 on October 16,...
🔴 Lipocine is trading 7.69% down
Lipocine is trading at $1.44, down 7.69%, with no confirmed company-specific announcement explaining the October 19 decline. - Supplied price context shows a...
🔴 Lipocine is trading 5.8% down
Lipocine is trading at $1.47, down -5.77%, with no confirmed company-specific announcement explaining the October 19 decline in available coverage. - The...
🔴 Lipocine is trading 11% down today amid biotech-sector weakness
Lipocine is trading 10.71% down at $1.50 on October 16, 2026, amid weakness across biotechnology stocks; no confirmed company-specific announcement explaining...
🔴 Lipocine is trading 5% down today amid biotech-sector weakness
Lipocine is trading at $1.59, down 5.36%, amid biotech-sector weakness; no confirmed company-specific catalyst has surfaced. - No company-specific...
🔴 Lipocine is trading 5% down as inflation concerns pressure tech shares; link unconfirmed
Lipocine is trading at $1.60, down 5.03%, amid broader technology-share pressure, though a direct link is unconfirmed. - Hotter-than-expected inflation revived...
🔴 Lipocine is trading 5% down in pre-market amid unconfirmed broader risk-off pressure
Lipocine is trading 5.04% lower at $1.60 in pre-market on October 15, versus its October 14 close of $1.69; broader risk-off conditions may be contributing,...
🔴 Lipocine is trading 5% down with no identified catalyst
Lipocine is trading at $1.63, down 5.16%, with no specific explanation identified for the October 12 decline. - No October 12 announcement or specific...
🔴 Lipocine is trading 10% down with no confirmed catalyst
Lipocine is trading at $1.74, down 10.10%, with no reliable report identifying a specific October 9 catalyst. - The latest company announcement was Health...
🔴 Lipocine is trading 5% down; cause remains unclear
Lipocine is trading at $1.83, down 5.14%; the cause of the October 9 decline remains unclear. - No reliable report identified a specific reason, and no...
🔴 Lipocine is trading 11% down — cause remains unclear
Lipocine is trading 11.33% down at $1.95, with no confirmed company-specific catalyst identified for the October 8 decline. - The latest company announcement...
🔴 Lipocine is trading 8.6% down — no confirmed catalyst identified
Lipocine is trading at $2.01, down 8.64%, with no confirmed company-specific overnight catalyst identified. - Its latest listed announcement was October 7...
🔴 Lipocine is trading 10.4% down in pre-market
Lipocine is trading 10.4% lower at $1.97 after a sharp reversal following a volatile session; no confirmed company-specific overnight catalyst was found. -...
🔴 Lipocine is trading 5.9% down in pre-market
Lipocine is trading 5.91% down at $2.07 in pre-market on October 8, versus its October 7 close of $2.20; no confirmed new overnight company catalyst was...
🔴 Lipocine is trading 10.5% down in after-hours trading
Lipocine is trading at $1.97, down 10.45% after hours, with no confirmed late-breaking catalyst in available reporting. - It closed at $2.20 on October 7,...
🔴 Lipocine is trading 6.4% down in after-hours trading with no late-breaking catalyst identified
Lipocine is trading 6.4% down at $2.06 after-hours; available reporting does not identify a late-breaking catalyst. - Lipocine closed the October 7, 2026...
Lipocine Announces Health Canada Approval for TLANDO® Testosterone Replacement Therapy
Lipocine Inc. announced that Health Canada has approved TLANDO®, an oral testosterone replacement therapy (TRT), for adult males with hypogonadism. The...